Nivolumab (new indication: colorectal cancer (CRC) with microsatellite-instability-high (MSI-H) or mismatch repair-deficient (dMMR), pre-treated patients, in combination with ipilimumab)

Subject:

• Active Substance: Nivolumab
• Name: Opdivo^®
• Therapeutic area: Colorectal cancer (CRC)
• Pharmaceutical company: Bristol-Myers Squibb GmbH & Co. KGaA

Time table:

• Start: 01.08.2021
• Final decision by G-BA: 20.01.2022

Final decision:

• No additional benefit proved